Insmed director Sharoky sells $637,650 of Insmed stock By Investing.com
Melvin Sharoky, a Director at INSMED Inc (), sold shares of the company’s common stock on August 17, 2026. The transaction involved the disposition of 5,000 shares.
The shares were sold at prices ranging from $127.51 to $127.61 per share, resulting in a total value of $637,650. This sale represents a direct disposition of common stock by Dr. Sharoky. The stock currently trades at $126.63 with a market capitalization of $26.5 billion. Despite the insider sale, analysts maintain a strong buy consensus with price targets suggesting 56% upside potential, and 12 analysts have recently revised their earnings estimates upward.
Following this transaction, Dr. Sharoky directly holds 246,081 shares of INSMED common stock. He also maintains indirect beneficial ownership of additional shares through various entities and accounts. These include 6,847 shares held by his spouse, and shares held as custodian for several individuals: 819 shares for Adler J. Wink, 5,423 shares for Nolan M. Wink, 5,007 shares for Sophie C. Wink, and 3,724 shares for Tulia L. Sharoky. Dr. Sharoky also holds indirect beneficial ownership through Padonia, LLC, where he is the managing member. According to InvestingPro analysis, INSMED appears overvalued at current levels based on Fair Value estimates. Investors seeking deeper insights can access comprehensive Pro Research Reports covering INSMED and 1,400+ other US equities.
In other recent news, Insmed reported a significant surge in its second-quarter revenue, driven by strong performances from its lung-disease drugs BRINSUPRI and ARIKAYCE. BRINSUPRI generated $309.2 million in the quarter, while ARIKAYCE added $116.3 million, marking an 8% increase from the previous year. This robust financial performance led Insmed to raise its full-year sales outlook for 2026, with BRINSUPRI’s revenue guidance now set between $1.25 billion and $1.4 billion. The company also increased its combined peak sales estimate for its three lead assets to over $14 billion. Additionally, Insmed received regulatory approval in Japan for Brinsupri, a treatment for non-cystic fibrosis bronchiectasis, for patients aged 12 and older. Following this approval, Mizuho raised its price target for Insmed shares to $195, maintaining an Outperform rating. H.C. Wainwright reiterated a Buy rating with a $220 price target, noting that Brinsupri is exceeding expectations early in its launch. These developments highlight Insmed’s expanding presence in the respiratory treatment market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
